Katoh M, Chishima S, Kiuchi N, Ikeo T, Sasaki Y
Pharmaceutical Development, Research Laboratories, Tanabe Seiyaku Co., Ltd, Saitama, Japan.
Thromb Haemost. 1995 Dec;74(6):1546-50.
Assay of the platelet fibrinogen-binding receptor glycoprotein (GP) IIb/IIIa is widely performed using 125I-labeled fibrinogen (125I-fibrinogen). We successfully devised a receptor binding assay system with high selectivity and sensitivity using a stable chemiluminescent acridinium derivative-I-labeled fibrinogen (acridinium-fibrinogen). Human fibrinogen is saline was labeled with equimolar acridinium dissolved in dimethylformamide, and allowed to react with gel-filtered human platelets in the presence of ADP. Acridinium-fibrinogen binding to GPIIb/IIIa was assayed by measuring chemiluminescence emitted on addition of 0.1 N NaOH containing 0.06% H2O2 in a luminometer. Non-specific binding was measured in the presence of 10 mM EDTA. Acridinium-fibrinogen binding to human platelets was rapid and reversible, specific and saturable, and dependent on ADP concentrations. Scatchard plot analysis revealed one class of binding sites with Kd of 326 nM and Bmax of 7.8 pmol/10(8) platelets. These values were comparable to the data obtained by using 125I-fibrinogen. Unlabeled fibrinogen, RGDS, and HHLGGAKQAGDV (fibrinogen gamma-chain 400-411) displaced acridinium-fibrinogen from its binding site with Ki values of 322 nM, 9.2 microM and 31.3 microM, respectively. Thus, this binding assay system may be useful in measuring the binding between platelet GPIIb/IIIa and fibrinogen without using a radioisotope.
血小板纤维蛋白原结合受体糖蛋白(GP)IIb/IIIa的检测广泛采用125I标记的纤维蛋白原(125I-纤维蛋白原)进行。我们成功设计了一种具有高选择性和灵敏度的受体结合检测系统,该系统使用稳定的化学发光吖啶鎓衍生物-I标记的纤维蛋白原(吖啶鎓-纤维蛋白原)。将人纤维蛋白原溶解于生理盐水中,用等摩尔溶解于二甲基甲酰胺的吖啶鎓进行标记,并使其在ADP存在的情况下与经凝胶过滤的人血小板反应。通过在发光计中测量加入含0.06% H2O2的0.1 N NaOH后发出的化学发光,来检测吖啶鎓-纤维蛋白原与GPIIb/IIIa的结合。在10 mM EDTA存在的情况下测量非特异性结合。吖啶鎓-纤维蛋白原与人血小板的结合迅速且可逆、具有特异性且可饱和,并且依赖于ADP浓度。Scatchard图分析显示存在一类结合位点,其解离常数(Kd)为326 nM,最大结合容量(Bmax)为7.8 pmol/10(8)个血小板。这些值与使用125I-纤维蛋白原获得的数据相当。未标记的纤维蛋白原、RGDS和HHLGGAKQAGDV(纤维蛋白原γ链400 - 411)分别以322 nM、9.2 μM和31.3 μM的抑制常数(Ki)从其结合位点取代吖啶鎓-纤维蛋白原。因此,这种结合检测系统可能有助于在不使用放射性同位素的情况下测量血小板GPIIb/IIIa与纤维蛋白原之间的结合。